FIZE Medical, a leader in fluid management optimization, is pleased to announce the successful closing of its $14 million Series A-4 funding round, led by Rapha Capital Management and its managed fund, Rapha Capital PE Life Sciences Fund VI, bringing total Series A funding to $29 million.
Read also – Freshket Secures US$8 Million Funding in Round
FIZE Medical is a commercial-stage company, solidifying its position as a pioneer in smart fluid management technology by expanding its geographical reach to the U.S., EU, and Asian markets. The company is also advancing its technological development and is set to soon launch AI-based predictive capabilities that will serve as a Decision Support System (DSS) through advanced data analysis. The market for AI-based technologies in critical care is currently estimated at approximately $12 billion annually.
Read also – NAIA Developments Partners with Vodafone Egypt to provide “Triple Play” across its various projects
Managing the hemodynamic status of critically ill patients is a major challenge for intensive care teams, as inaccurate diagnosis can lead to severe complications and is a leading cause of mortality in intensive care units. In the United States alone, over 4 million patients are hospitalized annually in intensive care units, with more than one-third experiencing circulatory shock, which carries a mortality rate of approximately 40%.
Additionally, around 50% of ICU patients develop AKI (Acute Kidney Injury) during hospitalization, resulting in mortality rates exceeding 20%. Early detection of AKI and Shock may significantly reduce morbidity and mortality rates.
The company’s technology meets these challenges with digital and continuous monitoring of kidney output. The data is streamlined in real-time to a bedside device and the patient’s electronic medical record (EMR), providing proactive alerts on changes in kidney function. By helping medical teams adjust therapies promptly, FIZE Medical’s groundbreaking innovation simplifies clinical decision-making , enables improved patient outcomes, aims to reduce mortality, and alleviates the workload on healthcare professionals.
The company saw an impressive surge in demand in 2024, driving rapid development and operational growth. Sima Faifman Kuchersky, FIZE Medical’s Chief Commercial Officer, noted: “In response to the growing demand across both domestic and international markets, we have strategically expanded our production capabilities—strengthening internal operations while leveraging our partnership with Cicor facilities in Vietnam to ensure scalability and efficiency.”
Over the next year, FIZE Medical plans to expand its platform to include advanced AI-driven patient condition predictions, intra-abdominal pressure measurement, and additional features aimed at enhancing patient care.
The Series A-4 financing was led by Rapha Capital Management, founded by its President, Kevin Slawin, M.D., a successful and experienced oncologic and robotic surgeon, focusing now on advancing disruptive healthcare technologies. Rapha Capital’s strategic guidance and expertise have been instrumental in FIZE Medical’s growth and development.
Joining this round is Valitas Venture Capital, known for its innovative approach to go-to-market strategies in the healthcare sector. Valitas Co-Founder and former Medtronic executive Tal Shnider will join FIZE Medical’s board as an observer, bringing valuable expertise in MedTech and commercialization.
Also participating in the round is eHealth Ventures, a strategic investor that provides access to global distribution channels, connections with key opinion leaders (KOLs), and a robust commercial network. Yair Hadar, representing eHealth Ventures, will join FIZE Medical’s board as an observer. eHealth Ventures’ involvement will play a critical role in accelerating FIZE Medical’s expansion into the U.S. market while reinforcing its leadership in smart fluid management technology.
Dror Zerem, CEO of FIZE Medical, commented: “We are thrilled to have Rapha Capital as the lead investor in this funding round, reaffirming their commitment to our mission. This funding, alongside support from Valitas Venture Capital, eHealth Ventures, and our existing investors, will enable us to accelerate our expansion into the U.S. and EU healthcare markets. With our innovative fluid management solutions, we look forward to positively impacting more hospitals and patients globally.”
FIZE-kUO® strives to empower clinicians with real-time, actionable data at their fingertips, enabling next-generation, AI-powered fluid management. The company consistently pushes the boundaries of fluid management technology, revolutionizing patient care and improving medical efficiencies worldwide.
About FIZE Medical
FIZE Medical cutting-edge technology provides medical professionals with real-time monitoring of renal output, a crucial vital sign that aids in the assessment of a patient’s hemodynamic status in various clinical settings, including operating rooms and critical care units. By utilizing our solution, healthcare providers detect and address potential complications promptly, reducing hospitalization-related complications and saving lives.
